secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066410
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25
--------------------------------------------------------------------------------

- Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.
- Net loss $39.5M vs $93.8M YoY; revenue $3.0M vs $1.4M.
- EMA submission expected 2H25 by partner Menarini; PREVAIL CVOT enrollment completed.
- Adele Gulfo appointed to Board of Directors in April 2025.
- R&D expenses $44.8M; SG&A $27.2M, up due to commercial launch prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/0000950170-25-066410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017025066410/nams-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer